Therapeutic Vaccine Market By Vaccine Type 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Therapeutic Vaccine Market
Therapeutic Vaccine Market: By Vaccine Type (Addiction, Neurological, Infectious, Autoimmune); By Technology (Autologous, Allogenic) & By Region (Europe, Asia-Pacific, Others)-Forecast (2016-2021)
Report Code : HCR 0397
Published: 05 October, 2016   No. of pages: 152

  • Report Description
  • Table of Contents
  • Customization Options
A vaccine is a biological medical product designed to stimulate antibodies inside the human body against any antibody attack. Vaccine helps in providing immunity against various infectious diseases. Vaccines can be broadly classified as prophylactic and therapeutic. Therapeutic vaccines also known as treatment vaccines spur the immune system to attack targeted tissue and is a biological combination designed to develop immunity against a diseased cell or tissues. Therapeutic vaccines are developed to treat ailments from various cancers, HIV and Alzheimer’s disease. Therapeutic vaccine is used for curing and prevention of cancer whereas prophylactic vaccines are only used for prevention of cancer. Globally increasing instance of HIV and cancer is expected to drive the demand for the therapeutic vaccine during the period of study.

 Therapeutic Vaccine Market

Geographically, North America dominates the therapeutic vaccine market driven by large pharmaceutical industry base, best in class healthcare infrastructure, strict regulation and higher spending on the healthcare by citizens of the region. North America was followed by Europe and Asia-Pacific as second and third largest markets for therapeutic vaccine market. Asia Pacific is projected to have the fastest growth, owing to rapidly developing medical infrastructure, increasing medical tourism, newer expanding pharmaceutical industry, and increasing awareness and spending on healthcare by population in developing nations such as China and India in this region.

This report identifies the global therapeutic vaccine market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to the therapeutic vaccine market.

This report segments the therapeutic vaccine market on the basis of vaccine type, technology and regional market as follows:
  • Therapeutic Vaccine Market research report is classified on the basis of vaccine type. Some of the major vaccine type covered in this report are as follows: Addiction Vaccines(Cocaine Addiction Vaccines, Nicotine Addiction Vaccines), Autoimmune Disease Vaccines( Diabetes (Type 1)(Diamyd (RHGAD65), BHT-3021, Tovaxin, TNFaKinoid) Cancer Vaccines (Cancer vaccines in development, Cancer vaccines approved for use)), Infectious Disease Vaccines (HIV/AIDS, Other infectious disease vaccines (outside HIV), Hepatitis C), Neurological disease vaccines, Parkinson’s disease vaccine and Other disease vaccines
  • Therapeutic Vaccine Market research report is classified on the basis of vaccine technology. Some of the major vaccine technology covered in this report are as follows: Autologous vaccine, allogenic vaccine
  • This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the therapeutic vaccine market. Some of the major companies’ profiles in detail are as follows:
  • Agenus, Inc.
  • GlaxoSmithKline
  • Novartis AG
  • Pfizer
  • Argos Therapeutic Inc.
1. Therapeutic Vaccine Market – Overview
2. Executive Summary
3. Therapeutic Vaccine Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Therapeutic Vaccine Market– Forces
   4.1. Drivers
      4.1.1. Increasing cases of cancer and HIV diseases
   4.2. Restraints
      4.2.1. Strict regulations in developed nations
   4.3. Opportunities
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Therapeutic Vaccine Market– Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Therapeutic Vaccine Market, By Type
   6.1. Addiction Vaccines
      6.1.1. Cocaine Addiction Vaccines
      6.1.2. Nicotine Addiction Vaccines
   6.2. Autoimmune Disease Vaccines
      6.2.1. Diabetes (Type 1)
            6.2.1.1. Diamyd (RHGAD65)
            6.2.1.2. BHT-3021
            6.2.1.3. Tovaxin
            6.2.1.4. TNFaKinoid
      6.2.2. Cancer Vaccines
            6.2.2.1. Cancer vaccines in development
            6.2.2.2. Cancer vaccines approved for use
   6.3. Infectious Disease Vaccines
      6.3.1. HIV/AIDS
      6.3.2. Other infectious disease vaccines (outside HIV)
      6.3.3. Hepatitis C
   6.4. Neurological disease vaccines
      6.4.1. Parkinson’s disease vaccine
      6.4.2. Other disease vaccines
7. Therapeutic Vaccine Market, By Technology
   7.1. Autologous Vaccine
   7.2. Allogeneic Vaccine
8. Therapeutic Vaccine Market, By Geography
   8.1. Europe
      8.1.1. Germany
      8.1.2. France
      8.1.3. Italy
      8.1.4. Spain
      8.1.5. Russia
      8.1.6. U.K.
      8.1.7. Rest of Europe
   8.2. Asia Pacific
      8.2.1. China
      8.2.2. India
      8.2.3. Japan
      8.2.4. South Korea
      8.2.5. Rest of Asia-Pacific
   8.3. North America
      8.3.1. U.S.
      8.3.2. Canada
      8.3.3. Mexico
   8.4. Rest of the World (RoW)
      8.4.1. Brazil
      8.4.2. Rest of RoW
9. Therapeutic Vaccine Market – Entropy
   9.1. Expansion
   9.2. Technological Developments
   9.3. Merger & Acquisitions, and Joint Ventures
   9.4. Supply- Contract
10. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
   10.1. Agenus, Inc.
   10.2. GlaxoSmithKline
   10.3. Novartis AG
   10.4. Pfizer
   10.5. Argos Therapeutic Inc.
   10.6. Merck & Co.
   10.7. Celldex Therapeutic Inc.
   10.8. Cytos Biotechnology AG
   10.9. Dendreon Corp
   10.10. Vaccinogen, Inc.
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix

   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Bibliography
   11.5. Compilation of Expert Insights
   11.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports